Fortunato Ciardiello
0000-0002-3369-4841
Publication & Citation Trends
Publications
0 total
Glycolytic heterogeneity drives metabolic-targeted therapy in pancreatic ductal adenocarcinoma
Cited by 2
Semantic Scholar
Pembrolizumab for high TMB castration-resistant prostate cancer: A precision medicine case report
Cited by 0
Semantic Scholar
IS AIRWAY STENT A DEFINITIVE TREATMENT FOR MANAGEMENT OF MALIGNANT CENTRAL AIRWAY OBSTRUCTION?
Cited by 0
Semantic Scholar
Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling.
Cited by 0
Semantic Scholar
BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Cited by 1
Semantic Scholar
BREAKWATER: Analysis of first-line encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant metastatic colorectal cancer.
Cited by 4
Semantic Scholar
Knowledge-informed multimodal cfDNA analysis improves sensitivity and generalization in cancer detection
Cited by 1
Semantic Scholar
Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer OA
Cited by 1
Semantic Scholar
Research Topics
Colorectal Cancer Treatments and Studies
(390)
Lung Cancer Treatments and Mutations
(284)
HER2/EGFR in Cancer Research
(172)
Cancer Treatment and Pharmacology
(134)
Gastric Cancer Management and Outcomes
(129)
Affiliations
AstraZeneca (United Kingdom)
Roche (Switzerland)
National Institutes of Health
Apple (Israel)
Yahoo (United Kingdom)